This activity was produced prior to the accelerated FDA approval of mosunetuzumab for the treatment of adult patients with relapsed or refractory follicular lymphoma following treatment with at least 2 prior lines of systemic therapy.

Community Practice Considerations: Emerging Bispecific Antibodies in NHL

Friday, January 20, 2023

1:00PM – 2:00PM ET

Please note this TeleECHO program is 1:00PM Eastern, 12:00PM Central, 11:00AM Mountain and 10:00AM Pacific.

PROGRAM OVERVIEW

This educational activity is designed to evaluate novel targets in NHL management, including consideration of the role of bispecific antibodies and combinations in development; assess clinical outcomes of key trials in NHL management, including diffuse large B-cell lymphoma, follicular lymphoma, and mantle cell lymphoma; and lastly to explain the current understanding of potential adverse events associated with novel therapies, including considerations regarding multidisciplinary management of adverse events.

PRESENTING FACULTY

P. Connor Johnson, MD
Instructor of Medicine, Harvard Medical School
Center for Lymphoma
Massachusetts General Hospital
Boston, MA

TARGET AUDIENCE

This activity is designed to meet the educational needs of community-based medical oncologists, hematologists, nurse practitioners, pharmacists, and other members of the multi-disciplinary oncology care team.

EDUCATIONAL OBJECTIVES

Upon completing this program, attendees should be able to:

  • Evaluate novel targets in non-Hodgkin’s lymphoma (NHL) management, including consideration of the role of bispecific antibodies and combinations in development
  • Assess clinical outcomes of key trials in NHL management, including diffuse large B-cell lymphoma, follicular lymphoma, and mantle cell lymphoma
  • Explain the current understanding of potential adverse events associated with novel therapies, including considerations regarding multi-disciplinary management of adverse events

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this virtually live activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the virtually live activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of patients with NHL.

CNE Credits: 1.0 ANCC Contact Hour.

CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/Complete Conference Management (CCM) is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.

Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education ACCME Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are scientifically based.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact: Med Learning Group at [email protected].

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]

Scroll to Top